BMG Pharma is an Italian company, founded in 2018 from the merger between BMG Pharma S.r.l. and Sigea S.r.l, a spin-ff of the University of Trieste
BMGPharma is specialized in bio-polymers and macro-molecules from which a new-generation of Hyaluronic Acid derivatives (Hyaluromimethic) has been developed, based on proprietary technology.
The company operates on a B2B business model for in-partnership development, registration and commercialization of products for dermo-aesthetics, oral-nasal, gynecology and nutraceuticals applications.
BMG Pharma is conducting clinical trials to obtain EU registration of different Hyaluromimethic formulations, for application as fillers in dermatology, orthopedics and ophthalmology
The company operates on a B2B business model for in-partnership development, registration and commercialization of products for dermo-aesthetics, oral-nasal, gynecology and nutraceuticals applications.
BMG Pharma is conducting clinical trials to obtain EU registration of different Hyaluromimethic formulations, for application as fillers in dermatology, orthopedics and ophthalmology
